Ueno, Melissa Lynne Johnson, Saar Gill, Elizabeth Claire Dees, Joseph Chao, Mathew Angelos, Olga Shestova, Jonathan Stuart Serody, Saul Priceman, Debora Barton, Ramona F. Reiss, MD: A Descriptive Study on the Treatment and Outcomes of Patients With Platinum-Sensitive, Advanced, BRCA or PALB2 Related Pancreatic Cancer Who Have Progressed on Rucaparib. Karasic, MD Charles Schneider, MD Natallia Izgur, RN Katherine Nathanson, MD Susan M. O’Hara, MD Ursina Teitelbaum, MD Thomas B. : Landscape of homologous recombination reversion mutations in pancreaticobiliary malignancies Schrock, Bahar Yilmazel, Douglas A Mata, Christine Vietz, Jeffrey S. Domchek, Kate Nathanson, Shannon Bailey, Natalie Danziger, James Thornton, Mark Hartman, Chenming Cui1, Lei Yang, Smruthy Sivakumar, Russell Madison1, Ethan Sokol, Alexa B. Lancet Oncology July 2022.īrennan Decker, Susan M. Vonderheide: Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase Ib/II trial. Reiss Rosemarie Mick Ursina Teitelbaum Mark O’Hara Charles Schneider Ryan Massa Thomas Karasic Rashmi Tondon Chioma Onyiah Mary Kate Gosselin Alyssa Donze Susan M. Carpenter, MBA, PhD: Multi-analyte prognostic signature including circulating tumor DNA and circulating tumor cells in patients with advanced pancreatic adenocarcinoma. Christensen, BA, Colleen Redlinger Tabery, BA, Amanda Anderson, PhD, Megan Slade, BS, Michael LaRiviere, MD, Stephanie S. Teitelbaum, MD, Janae Romeo, MBE, BA, Taylor A. Till, MD, PhD, Wei-Ting Hwang, PhD, Jennifer R. Hematology/Oncology Clinics of North America Sep 2022. Reiss: PARP Inhibitors and Other Novel, Targeted Therapeutics in Pancreatic Adenocarcinoma. Selected Publications William Chapin and Kim A.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |